Galectin Therapeutics Inc
GALT
NASDAQ
Biotechnology
$3.44
USD
-0.09 (-2.55%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $356.00M
Volume 388.2K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-26.25M
TTM
+41.9%
YoY
Operating Cash Flow
$-20.05M
TTM
+46.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 1.4 | 1.4 | 1.6 | 1.4 | 1.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 7.9 | 4.6 | 4.2 | 3.4 | 4.1 |
Operating Income | -7.9 | -4.6 | -4.2 | -3.4 | -4.1 |
EBITDA | -7.9 | -4.6 | -4.2 | -3.4 | -4.1 |
Other Income / Expense | -0.0 | -1.1 | -2.2 | -0.2 | 1.0 |
Total Other Income / Expense | -1.7 | -2.9 | -4.0 | -2.1 | -1.0 |
Income Before Income Taxes | -9.6 | -7.5 | -8.2 | -5.5 | -5.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.6 | -7.5 | -8.2 | -5.5 | -5.0 |
Consolidated Net Income / Loss | -9.6 | -7.5 | -8.2 | -5.5 | -5.0 |
Net Income Attributable to Common Shareholders | -9.6 | -7.6 | -8.2 | -5.6 | -5.1 |
Basic EPS | -$0.15 | -$0.12 | -$0.13 | -$0.09 | -$0.08 |
Diluted EPS | -$0.15 | -$0.12 | -$0.13 | -$0.09 | -$0.08 |
Basic Shares Outstanding | 63.2M | 63.4M | 64.2M | 64.8M | 65.8M |
Diluted Shares Outstanding | 63.2M | 63.4M | 64.2M | 64.8M | 65.8M |